<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neurosci</journal-id>
<journal-id journal-id-type="hwp">jneuro</journal-id>
<journal-id journal-id-type="pmc">jneurosci</journal-id>
<journal-id journal-id-type="publisher-id">J. Neurosci</journal-id>
<journal-title-group>
<journal-title>The Journal of Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">0270-6474</issn>
<issn pub-type="epub">1529-2401</issn>
<publisher>
<publisher-name>Society for Neuroscience</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31000585</article-id>
<article-id pub-id-type="pmc">6595955</article-id>
<article-id pub-id-type="publisher-id">2723-18</article-id>
<article-id pub-id-type="doi">10.1523/JNEUROSCI.2723-18.2019</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Articles</subject>
<subj-group>
<subject>Neurobiology of Disease</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Enhanced Dendritic Inhibition and Impaired NMDAR Activation in a Mouse Model of Down Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-1557-5352</contrib-id>
<name>
<surname>Schulz</surname>
<given-names>Jan M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Knoflach</surname>
<given-names>Frederic</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hernandez</surname>
<given-names>Maria-Clemencia</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-4006-1663</contrib-id>
<name>
<surname>Bischofberger</surname>
<given-names>Josef</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><sup>1</sup>Department of Biomedicine, University of Basel, CH-4056 Basel, Switzerland, and </aff>
<aff id="aff2"><sup>2</sup>Pharma Research and Early Development, Discovery Neuroscience Department, F. Hoffmann-La Roche Ltd, CH-4058 Basel, Switzerland</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence should be addressed to Josef Bischofberger at <email>Josef.Bischofberger@unibas.ch</email>.</corresp>
<fn fn-type="con">
<p>Author contributions: J.M.S., M.-C.H., and J.B. designed research; J.M.S. and F.K. performed research; J.M.S. analyzed data; J.M.S. and J.B. wrote the first draft of the paper; J.M.S. and J.B. wrote the paper; F.K., M.-C.H., and J.B. edited the paper.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>26</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>26</day>
<month>12</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 6 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>39</volume>
<issue>26</issue>
<fpage>5210</fpage>
<lpage>5221</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>10</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>9</day>
<month>4</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>4</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 the authors</copyright-statement>
<copyright-year>2019</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="zns02619005210.pdf"></self-uri>
<abstract>
<p>Down syndrome (DS) or Trisomy 21 is a developmental disorder leading to cognitive deficits, including disruption of hippocampus-dependent learning and memory. Enhanced inhibition has been suggested to underlie these deficits in DS based on studies using the Ts65Dn mouse model. Here we show that, in this mouse model, GABAergic synaptic inhibition onto dendrites of hippocampal pyramidal cells is increased. By contrast, somatic inhibition was not altered. In addition, synaptic NMDAR currents were reduced. Furthermore, dendritic inhibition was mediated via nonlinear α5-subunit containing GABA<sub>A</sub>Rs that closely matched the kinetics and voltage dependence of NMDARs. Thus, enhanced dendritic inhibition and reduced NMDA currents strongly decreased burst-induced NMDAR-mediated depolarization and impaired LTP induction. Finally, selective reduction of α5-GABA<sub>A</sub>R-mediated inhibition rescued both burst-induced synaptic NMDAR activation and synaptic plasticity. These results demonstrate that reduced synaptic NMDAR activation and synaptic plasticity in the Ts65Dn mouse model of DS can be corrected by specifically targeting nonlinear dendritic inhibition.</p>
<p><bold>SIGNIFICANCE STATEMENT</bold> Mild to moderate intellectual disability is a prominent feature of Down syndrome. Previous studies in mouse models suggest that increased synaptic inhibition is a main factor for decreased synaptic plasticity, the cellular phenomenon underlying memory. The present study shows that increased inhibition specifically onto dendrites together with reduced NMDAR content in excitatory synapses may be the cause. Reducing a slow nonlinear component that is specific to dendritic inhibitory inputs and mediated by α5 subunit-containing GABA<sub>A</sub> receptors rescues both NMDAR activation and synaptic plasticity.</p>
</abstract>
<kwd-group>
<kwd>alpha5 GABAA receptors</kwd>
<kwd>CA1 pyramidal cells</kwd>
<kwd>dendritic inhibition</kwd>
<kwd>Down syndrome</kwd>
<kwd>hippocampus</kwd>
<kwd>NMDA receptors</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>